CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025

Core Insights - CytomX Therapeutics, Inc. will report its third quarter financial results on November 6, 2025, after U.S. market close [1] - A conference call and webcast will follow the announcement at 5:00 p.m. ET / 2:00 p.m. PT [1] Company Overview - CytomX is a clinical-stage biopharmaceutical company focused on oncology, developing conditionally activated, masked biologics localized to the tumor microenvironment [3] - The company utilizes its PROBODY therapeutic platform to create safer and more effective cancer therapies [3] - Current clinical-stage pipeline includes CX-2051, a masked ADC targeting EpCAM, and CX-801, a masked interferon alpha-2b PROBODY cytokine [3] - CX-2051 has potential applications in multiple EpCAM-expressing epithelial cancers, including colorectal cancer [3] - CX-801 is designed for use in both immuno-oncology sensitive and insensitive tumors [3] - CytomX has established collaborations with major oncology leaders such as Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna [3]